4.6 Article

Taste alterations and oral discomfort in patients receiving chemotherapy

Journal

SUPPORTIVE CARE IN CANCER
Volume 29, Issue 12, Pages 7431-7439

Publisher

SPRINGER
DOI: 10.1007/s00520-021-06316-4

Keywords

Chemotherapy; Taste alterations; CiTAS; Acidity; PH; Saliva; Cancer

Funding

  1. Innovationsfonden (Denmark)

Ask authors/readers for more resources

This study found that 93% of cancer patients reported taste alterations, with patient age, oral discomfort, and swallowing difficulty identified as significant factors contributing to these alterations. However, no correlation was found between patients' acidity of saliva and taste alterations and oral discomfort.
Purpose Taste alterations (TA) and oral discomfort in cancer patients are neglected side effects of the disease and treatments. They contribute to poor appetite, decrease food intake and affect quality of life, leading to adverse outcomes such as malnutrition and depression. The study aimed to explore TAs in relation to other oral conditions causing discomfort in cancer patients. Additionally, the correlation between patients' acidity of saliva and experienced TAs and oral discomfort was evaluated. Methods A case study including 100 patients diagnosed with cancer receiving chemotherapy or immunotherapy. Data were collected using two questionnaire forms: the Chemotherapy-induced Taste Alteration Scale (CiTAS) and an additional information questionnaire. Saliva samples were collected for each patient and measured with a pocket pH meter. Data were analysed using descriptive statistics, and comparisons were performed using the Kruskal-Wallis H test, Mann-Whitney U test and Fisher's exact test. Results The prevalence of reported TAs was 93%. Patient age, oral discomfort and swallowing difficulty were found to be significant factors for experienced TAs (p < 0.05). No correlation between patients' acidity of saliva and reported TAs and oral discomfort was found. Conclusion CiTAS proved to be a convenient tool to collect information about TAs in cancer patients. Using the CiTAS tool, a high prevalence (93%) of reported TAs in cancer patients receiving chemo- or immunotherapy was found. CiTAS provides a fast and cheap recognition of symptoms and causes of TAs that can be addressed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available